Skip to main content

Table 3 Treatment-emergent adverse event rates per participant per month for combined trial arms among regions a

From: Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials

Study program Treatment group North America Western Europe Australia/South Africa Japan Asia Eastern Europe/Russia South America/Mexico
IDENTITY Placebo 0.52 ± 1.31SA,EE,JP 0.37 ± 0.78EE,JP 0.34 ± 0.48 0.14 ± 0.17 WE,NA 0.31 ± 0.63 0.31 ± 0.84WE,NA 0.25 ± 0.56NA
Semagacestat 140 mg PO 1.10 ± 1.59EE,JP 0.76 ± 1.02EE 0.87 ± 0.85EE 0.57 ± 0.86NA 0.69 ± 0.89 0.62 ± 1.28AU,WE,NA 0.88 ± 1.36
EXPEDITION Placebo 0.40 ± 0.57SA,EE,JP,WE 0.24 ± 0.27SA,EE,NA 0.42 ± 0.31SA,EE, JP,WE 0.16 ± 0.13AU,NA 0.31 ± 0.42EE 0.19 ± 0.40AS,AU,WE,NA 0.22 ± 0.28AU,NA
Solanezumab 400 mg IV 0.41 ± 0.68SA,EE,JP,WE 0.24 ± 0.63NA 0.51 ± 1.04SA,EE 0.21 ± 0.22NA 0.29 ± 0.68EE 0.11 ± 0.13AS,AU,NA 0.19 ± 0.29AU,NA
  1. aData are presented as mean ± standard deviation. SA = P < 0.01 vs South America/Mexico; EE = P < 0.01 vs Eastern Europe/Russia; AS = P < 0.01 vs Asia; JP = P < 0.01 vs Japan; AU = P < 0.01 vs Australia/South Africa; WE = P < 0.01 vs Western Europe; NA = P < 0.01 vs North America; IV = Intravenously; PO = By mouth.